Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

A Closer Look at CAR T-Cell Therapy — Successes, Challenges, And Future

Chimeric antigen receptor T-cell therapy enhances immune response against cancer, with promising results in hematological malignancies and ongoing advancements.

13 Nov 2024

Novel Approach to Predict and Optimize CAR-T Cell Therapy

A significant turning point in the battle against cancer has been the recent development of CAR-T technology.

30 Oct 2024

St. Jude Scientists Reveal Role of Non-Coding DNA Variants in Childhood Leukemia

St. Jude Children's Research Hospital scientists have identified specific DNA variants in the non-coding regions of the genome contributing to chemotherapy resistance in acute lymphoblastic leukemia (ALL).

2 May 2024

Precision Combination Therapy Better Controls High-Risk Subtypes of B-ALL in Mouse Models

Despite having an overall survival rate of 94%, B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, can prove challenging to treat, with survival among relapsed or resistant cases falling between 30-50%.

9 Apr 2024

RNA-Seq Unveils Molecular Subtypes for Tailored Pediatric B-ALL Treatment

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, representing more than 30% of all pediatric cases.

31 Jan 2024

Potential approach to improve solid tumor T cell therapy

Researchers at the Perelman School of Medicine at the University of Pennsylvania have been working on a preclinical study that focuses on a new strategy that uses a “one-two punch” to assist T cells in attacking solid tumors.

17 Mar 2023

Study examines the role of dietary vitamin A in preventing or treating AAP

Consuming a diet rich in vitamin A or its analogs may help prevent children and young adults with acute lymphoblastic leukemia (ALL) reduce their risk of developing painful pancreas inflammation during chemotherapy treatment.

16 Mar 2023

Researchers discover effective therapy for pediatric T-acute leukemia

The most frequent type of malignancy in kids is acute lymphoblastic leukemia (ALL).

27 Jun 2022

Looking at protein activity gives a complete picture of leukemia's weaknesses

Blocking a protein chain reaction makes childhood leukemia cells more sensitive to an existing targeted treatment, a new study shows.

28 Feb 2022

Leukemia-on-a-chip; The Future of Preventing Therapy Resistance?

We speak to Dr. Chao Ma, one of the speakers at SLAS 2022, about his groundbreaking 'leukemia-on-a-chip' technology and its future within therapy resistance.

From Society for Laboratory Automation and Screening (SLAS) 27 Jan 2022

Next-generation sequencing for minimal residual disease proven more sensitive than flow cytometry

In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.

2 Dec 2021

Study reveals how two separate DNA changes may predict aggressive childhood leukemias

New research published today in JAMA Oncology reports how two separate DNA changes appear to predict aggressive childhood leukemias when they occur in combination.

From The University of Utah 20 Aug 2021

Small molecular changes can have dramatic impact on the CAR T cell function

When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn't respond, they went back to the drawing board to determine why.

23 Apr 2021

Researchers uncover a key genetic culprit in the development of acute lymphoblastic leukemia

Using a widely known field of mathematics designed mainly to study how digital and other forms of information are measured, stored and shared, scientists at Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center say they have uncovered a likely key genetic culprit in the development of acute lymphoblastic leukemia (ALL).

21 Apr 2021

Engineered safety switch reduces CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

5 Mar 2021

Electron Microscopy and Image Analysis in Biological Drug Manufacturing Processes

This article discusses how the biological drug manufacturing process can be improved by electron microscopy and image analysis.

From Hitachi High-Tech Europe 4 Feb 2021

Yale scientists discover novel metabolic gatekeeper mechanism for leukemia

In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease. The findings were published online today in the Proceedings of the National Academy of Sciences (PNAS).

2 Feb 2021

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.

7 Jan 2021

Study: DOT1L enzyme is essential for humoral immune responses

Communication, serendipity and an enzyme called DOT1L have all combined to produce some exciting findings into the immune system's B cells and T cells by two groups of Monash Biomedicine Discovery Institute (BDI) scientists.

17 Dec 2020

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.

8 Dec 2020